Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders (2016 - 2021)
Historic Net Income towards Common Stockholders for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $22.5 million.
- Neurocrine Biosciences' Net Income towards Common Stockholders rose 13906.25% to $22.5 million in Q3 2021 from the same period last year, while for Dec 2021 it was $96.9 million, marking a year-over-year increase of 6313.13%. This contributed to the annual value of $37.0 million for FY2019, which is 7532.09% up from last year.
- Neurocrine Biosciences' Net Income towards Common Stockholders amounted to $22.5 million in Q3 2021, which was up 13906.25% from $42.3 million recorded in Q2 2021.
- Over the past 5 years, Neurocrine Biosciences' Net Income towards Common Stockholders peaked at $79.6 million during Q2 2020, and registered a low of -$102.1 million during Q1 2019.
- Its 5-year average for Net Income towards Common Stockholders is $3.9 million, with a median of $20.7 million in 2018.
- In the last 5 years, Neurocrine Biosciences' Net Income towards Common Stockholders crashed by 29366.3% in 2017 and then skyrocketed by 96757.99% in 2019.
- Quarter analysis of 5 years shows Neurocrine Biosciences' Net Income towards Common Stockholders stood at $6.9 million in 2017, then skyrocketed by 172.82% to $18.8 million in 2018, then skyrocketed by 80.84% to $34.0 million in 2019, then tumbled by 269.35% to -$57.6 million in 2020, then surged by 139.06% to $22.5 million in 2021.
- Its Net Income towards Common Stockholders was $22.5 million in Q3 2021, compared to $42.3 million in Q2 2021 and $32.1 million in Q1 2021.